Patents Assigned to Allergan, Inc.
  • Patent number: 10406213
    Abstract: Methods for treating a patient suffering from a medication overuse headache disorder are provided. The methods comprise administering to a patient suffering from a medication overuse disorder a Clostridial toxin. The toxin is administered to the frontalis, corrugator, procerus, occipitalis, temporalis, trapezius and cervical paraspinal muscles of the patient.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: September 10, 2019
    Assignee: Allergan, Inc.
    Inventors: Catherine C. Turkel, Sheena K. Aurora, Mitchell F. Brin
  • Patent number: 10407382
    Abstract: Described herein are compounds that are EP4 agonists and antagonists which are useful for treating a variety of pathological conditions associated with activity of EP4 receptors.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: September 10, 2019
    Assignee: ALLERGAN, INC.
    Inventors: David W. Old, Christopher D. Hein
  • Patent number: 10406168
    Abstract: Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the prostamide component may be encapsulated by the polymeric component. The present implants include oil-in-oil emulsified implants or microparticles. Methods of producing the present implants are also described. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: September 10, 2019
    Assignee: Allergan, Inc.
    Inventors: Patrick M. Hughes, Michele Boix, Christian Sarrazin, Marina Do
  • Patent number: 10398707
    Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: September 3, 2019
    Assignee: Allergan, Inc.
    Inventor: Patrick M. Hughes
  • Patent number: 10391199
    Abstract: The present specification discloses porous materials, methods of forming such porous materials, biocompatible implantable devices comprising such porous materials, and methods of making such biocompatible implantable devices.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: August 27, 2019
    Assignee: ALLERGAN, INC.
    Inventors: Futian Liu, Nicholas J. Manesis, Alexei Goraltchouk, Dimitri Stroumpoulis
  • Patent number: 10392382
    Abstract: The present invention provides a compound, that is a 1-({halo-2-[(2-hydrocarbyl or substituted hydrocarbyl)oxy]phenyl}methyl)-(fused bicyclic nitrogen heteroaryl) carboxylic acid or an ester or sulfonamide thereof. The compound may be represented by the following formula Wherein R1, R2, R3, R4 A, X, W, Z and Y are as defined in the specification. The compounds may be administered to treat DP, FP, EP1, TP and/or EP4 receptor-mediated diseases or conditions.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: August 27, 2019
    Assignee: ALLERGAN, INC.
    Inventors: William R. Carling, Jose L. Martos, Jussi J. Kangasmetsa, Jenny W. Wang, David F. Woodward
  • Patent number: 10383942
    Abstract: A topical pharmaceutical composition comprising tazarotene and one or more of an anti-inflammatory or anti-bacterial agent. Also provided is a method for treating skin conditions, such as acne utilizing the above topical pharmaceutical composition.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: August 20, 2019
    Assignee: Allergan, Inc.
    Inventors: Michael G. Oefelein, Jeffrey R. Ehrhardt, Gurpreet Ahluwalia
  • Publication number: 20190247476
    Abstract: Pharmaceutical compositions that stabilize a Clostridial toxin active ingredient are described. The compositions can be liquid or solid compositions, and comprise a surfactant and an antioxidant. In some embodiments, the compositions comprise a surfactant selected from a poloxamer and a polysorbate; an antioxidant selected from methionine, N-acetyl cysteine, ethylenediaminetetraacetic acid and combinations thereof; and, optionally, a tonicity agent and/or a lyoprotector selected from, for example, trehalose and sucrose.
    Type: Application
    Filed: September 13, 2017
    Publication date: August 15, 2019
    Applicant: Allergan, Inc.
    Inventors: Maurice Abiad, Bhas Dani, Evgenyi Shalaev
  • Patent number: 10369190
    Abstract: Pharmaceutical compositions that stabilize a Clostridial toxin active ingredient are described. The compositions can be liquid or solid compositions, and comprise a surfactant and an antioxidant. In some embodiments, the compositions comprise a surfactant selected from a poloxamer and a polysorbate; an antioxidant selected from methionine, N-acetyl cysteine, ethylenediaminetetraacetic acid and combinations thereof, and, optionally, a tonicity agent and/or a lyoprotector selected from, for example, trehalose, sucrose.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: August 6, 2019
    Assignee: Allergan, Inc.
    Inventors: Maurice Abiad, Bhas Dani, Evgenyi Shalaev
  • Patent number: 10369500
    Abstract: Methods and devices for treating lipoaspirate for use in fat grafting procedures are provided and generally include a canister for containing lipoaspirate, a separation mechanism structured to separate both oils and other materials from cellular components of lipoaspirate contained in the canister. The separation mechanism includes filters having different filtering capacities, for example, different pore sizes.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: August 6, 2019
    Assignee: Allergan, Inc.
    Inventors: Zachary Dominguez, Justin Schwab, Tiago Bertolote, Jason Metzner, Ethan Franklin
  • Patent number: 10363214
    Abstract: Compositions and methods for treating dry age related macular degeneration (dry AMO) by administration to an intraocular location of an anti-neovascular agent (such as bevacizumab) in either a liquid or solid polymeric vehicle (or both), such as a biodegradable hyaluronic acid or PLGA (or PLA).
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: July 30, 2019
    Assignee: Allergan, Inc.
    Inventors: Scott M. Whitcup, Michael R. Robinson, Wendy M. Blanda, Patrick M. Hughes, James A. Burke
  • Patent number: 10357615
    Abstract: Described herein are syringe extrusion accessories comprising: a handle operatively coupled to an attachment portion configured to attach to a syringe; and at least one pawl operatively coupled to the handle and configured to engage with a plunger of the syringe, wherein the syringe extrusion accessory is configured to transfer a substantially perpendicular force applied to the handle to an axial force to push the plunger and extrude a product from the syringe.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: July 23, 2019
    Assignee: ALLERGAN, INC.
    Inventors: Ethan W. Franklin, Justin J. Schwab
  • Patent number: 10350055
    Abstract: Methods for texturing surgical implants, for example, breast implants, are provided. The methods include the use of computer controlled 3D printing of a sacrificial material to create a textured surface on an unfinished surface of the implant.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: July 16, 2019
    Assignee: ALLERGAN, INC.
    Inventors: Robert Nieto, Zachary Dominguez
  • Patent number: 10345306
    Abstract: The present specification discloses a retargeted endopeptidase pharmaceutical wherein the activity has been determined by the methods disclosed.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: July 9, 2019
    Assignee: Allergan, Inc.
    Inventors: Joanne Wang, Hong Zhu, Dianne D. Hodges, Ester Fernandez-Salas
  • Patent number: 10329284
    Abstract: Described herein are ester prodrugs of gamma-lactam compounds of Formula (I): or pharmaceutically acceptable salt thereof, and methods of use of such compounds for the treatment of ocular diseases including, among other things, glaucoma and macular degeneration.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: June 25, 2019
    Assignee: ALLERGAN, INC.
    Inventors: Robert M. Burk, Wha Bin Im
  • Patent number: 10328086
    Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce at least one symptom of an ocular condition, such as glaucoma.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: June 25, 2019
    Assignee: Allergan, Inc.
    Inventor: Patrick M. Hughes
  • Patent number: 10314887
    Abstract: Ophthalmic products and related methods are described herein. These methods include a stabilizing composition comprising a therapeutically active agent which is separated from a liquid vehicle composition by a barrier. The barrier may be removed to allow the two compositions to mix to provide an ophthalmically acceptable liquid comprising the therapeutically active agent.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: June 11, 2019
    Assignee: Allergan, Inc.
    Inventors: Anuradha V. Gore, Sai M. Shankar, Sukhon Likitlersuang, Chetan P. Pujara, Sesha Neervannan
  • Patent number: 10307368
    Abstract: Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: June 4, 2019
    Assignee: ALLERGAN, INC.
    Inventors: Richard Graham, Peter Bakhit, Orest Olejnik
  • Patent number: 10308711
    Abstract: Disclosed herein are monospecific HCAb antibodies with antigen-binding specificity to PDGF and bispecific antibodies with antigen-binding specificities to PDGF-2 and VEGF or to PDGF and ANG-2.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: June 4, 2019
    Assignee: Allergan, Inc.
    Inventors: Yanbin Liang, Daniel W. Gil
  • Patent number: 10300169
    Abstract: Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes. A macromolecular matrix may comprise a hyaluronic acid component crosslinked to a silk fibroin component.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: May 28, 2019
    Assignee: Allergan, Inc.
    Inventors: Xiaojie Yu, Darin J. Messina, Elizabeta Pavlovic, Cunqi Cui, Kate M. Smither